Zobrazeno 1 - 10 of 21 pro vyhledávání: '"Laurence Baudrin"'
1
Second-line therapy in elderly patients with advanced nonsmall cell lung cancer
Autor: Elisabeth, Quoix, Virginie, Westeel, Lionel, Moreau, Eric, Pichon, Armelle, Lavolé, Jérome, Dauba, Didier, Debieuvre, Pierre Jean, Souquet, Laurence, Bigay-Game, Eric, Dansin, Michel, Poudenx, Olivier, Molinier, Fabien, Vaylet, Denis, Moro-Sibilot, Denis, Herman, Helene, Sennelart, Jean, Tredaniel, Bertrand, Mennecier, Franck, Morin, Laurence, Baudrin, Bernard, Milleron, Gérard, Zalcman, N, Le Flour
Publikováno v: European Respiratory Journal
European Respiratory Journal, European Respiratory Society, 2014, 43, pp.240--9. ⟨10.1183/09031936.00048213⟩
European Respiratory Journal, 2014, 43, pp.240--9. ⟨10.1183/09031936.00048213⟩
There is no dedicated study on second-line treatment for elderly patients with advanced nonsmall cell lung cancer (NSCLC). We report the results on second-line erlotinib therapy from our previously published phase III study comparing single-agent the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b669b7c6d336cdca82ec2ec8bc816bea
https://doi.org/10.1183/09031936.00048213
Zobrazit plný text záznamu
2
Concurrent chemoradiation for elderly patients with locally advanced non-small-cell lung cancer: still a controversial issue
Autor: Virginie Westeel, Laurence Baudrin, Bernard Milleron, Elisabeth Quoix
Publikováno v: Aging Health. 8:119-122
Evaluation of: Jalal SI, Riggs HD, Melnyk A et al. Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation doc
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bdd3a2dea8495e06c76d0c6c23bf9a96
https://doi.org/10.2217/ahe.12.14
Zobrazit plný text záznamu
3
Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study)
Autor: Didier Debieuvre, Fabrice Barlesi, Bernard Lebeau, Bernard Milleron, Franck Morin, Fabien Vaylet, Jean-François Morère, Gérard Zalcman, Thierry Urban, Pierre-Jean Souquet, Virginie Westeel, Laurence Baudrin, Valérie Gounant, Jeanne-Marie Bréchot, Denis Moro-Sibilot
Publikováno v: Lung Cancer
Lung Cancer, Elsevier, 2010, 70 (3), pp.301-307. ⟨10.1016/j.lungcan.2010.03.003⟩
Lung Cancer, Elsevier, 2010, 70 (3), pp.301-307. 〈10.1016/j.lungcan.2010.03.003〉
Lung Cancer, 2010, 70 (3), pp.301-307. ⟨10.1016/j.lungcan.2010.03.003⟩
International audience; BACKGROUND: To compare 3 treatment strategies in chemotherapy naive patients with advanced NSCLC and a PS 2-3. PATIENTS AND METHODS: Patients were assigned to gefitinib 250mg daily (n=43) or to gemcitabine (1250mg/m(2) d 1, 8
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a4ace6463dd7eba3ceb5128281ca711
https://doi.org/10.1016/j.lungcan.2010.03.003
Zobrazit plný text záznamu
4
IFCT-0401 Trial: A Phase II Study of Gefitinib Administered as First-Line Treatment in Advanced Adenocarcinoma with Bronchioloalveolar Carcinoma Subtype
Autor: Jacques, Cadranel, Elisabeth, Quoix, Laurence, Baudrin, Pierre, Mourlanette, Denis, Moro-Sibilot, Jean-François, Morere, Pierre-Jean, Souquet, Jean-Charles, Soria, Franck, Morin, Bernard, Milleron, N, Establier
Publikováno v: Journal of Thoracic Oncology. 4(9):1126-1135
Purpose Intergroupe Francophone de Cancerologie Thoracique-0401 phase II trial aimed to evaluate the efficacy and safety of gefitinib as a first-line treatment for patients with adenocarcinoma with bronchioloalveolar carcinoma subtype (ADC-BAC). Meth
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15ba11dfd5a6ed561530efbd70dd1a92
Zobrazit plný text záznamu
5
Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network
Autor: Hélène Blons, Benjamin Besse, Jérôme Solassol, Michèle Legrain, Isabelle Rouquette, P. de Cremoux, Ivan Bièche, Anne-Claire Voegeli, Pascale Tomasini, Jacques Cadranel, Marie Wislez, F. De Fraipont, Laurence Baudrin, Fabienne Escande, Jean-Luc Prétet, Elisabeth Quoix, E. Favre-Guillevin, Nathalie Prim, Franck Morin, Roger Lacave, Ludovic Lacroix, A.-M. Ruppert, Isabelle Nanni-Metellus, Sarab Lizard, Anne Cayre, Gérard Zalcman, Michèle Beau-Faller
Publikováno v: Annals of Oncology
Annals of Oncology, Oxford University Press (OUP), 2014, 25, pp.126--31. ⟨10.1093/annonc/mdt418⟩
Annals of Oncology, 2014, 25, pp.126--31. ⟨10.1093/annonc/mdt418⟩
Annals of Oncology, Elsevier, 2014, 25, pp.126--31. ⟨10.1093/annonc/mdt418⟩
International audience; BACKGROUND: There is scarce data available about epidermal growth factor receptor (EGFR) mutations other than common exon 19 deletions and exon 21 (L858R) mutations. PATIENTS AND METHODS: EGFR exon 18 and/or exon 20 mutations
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f9bdfc634c42ac78a34089935ed1474
https://hal.umontpellier.fr/hal-02181347
Zobrazit plný text záznamu
6
Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial
Autor: Pierre Mourlanette, Denis Moro-Sibilot, Jean-Charles Soria, Laurence Baudrin, Marie Wislez, Isabelle Monnet, Michael Duruisseaux, D. Coëtmeur, Virginie Westeel, Jacques Cadranel, Franck Morin, Elisabeth Quoix, Jean-François Morère
Publikováno v: Journal of Thoracic Oncology
Journal of Thoracic Oncology, Lippincott, Williams & Wilkins, 2012, 7 (9), pp.1423-1431. 〈10.1097/JTO.0b013e31825ab897〉
Journal of Thoracic Oncology, 2012, 7 (9), pp.1423-1431. ⟨10.1097/JTO.0b013e31825ab897⟩
Journal of Thoracic Oncology, Lippincott, Williams & Wilkins, 2012, 7 (9), pp.1423-1431. ⟨10.1097/JTO.0b013e31825ab897⟩
International audience; HYPOTHESIS:: This study explored whether chemotherapy after first-line gefitinib was effective in patients with advanced lepidic predominant adenocarcinoma (LPA), formerly advanced bronchioloalveolar carcinoma, who were enroll
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1d3c715e4e168ea19bb1e4428f2253b
https://pubmed.ncbi.nlm.nih.gov/22767177
Zobrazit plný text záznamu
7
Routine administration of a single dose of cisplatin ≥ 75 mg/m2 after short hydration in an outpatient lung-cancer clinic
Autor: Sophie Danel, Laure Belmont, Lise Rosencher, Jacques Cadranel, Anne-Marie Ruppert, Valérie Gounant, Bernard Milleron, C. Epaud, Armelle Lavolé, Laurence Baudrin
Publikováno v: Bulletin du cancer. 99(4)
Cisplatin is a pivotal drug in combined chemotherapy for non-small cell and small-cell lung cancers (NSCLC or SCLC), but its renal toxicity limits its use. Current guidelines recommend 24 h hydration: thus hospitalization is required. The aim of this
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23be9815b4beb51de49aec6ff08af664
https://pubmed.ncbi.nlm.nih.gov/22450449
Zobrazit plný text záznamu
9
Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer
Autor: Christos Chouaid, Bernard Milleron, Marie Wislez, Armelle Lavolé, Gilles Raguin, Laurence Baudrin, Pierre-Marie Girard, Gilles Pialoux, Jacques Cadranel
Publikováno v: Lung Cancer
Lung Cancer, Elsevier, 2009, 65 (3), pp.345-50. ⟨10.1016/j.lungcan.2008.11.018⟩
Lung Cancer, 2009, 65 (3), pp.345-50. ⟨10.1016/j.lungcan.2008.11.018⟩
International audience; OBJECTIVE: To evaluate the impact of highly active antiretroviral therapy (HAART) on survival in HIV infected patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: All consecutive HIV infected patients with N
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::698d156f25901086cd96398c9e3f7aeb
https://hal.sorbonne-universite.fr/hal-00596986
Zobrazit plný text záznamu
10
Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib
Autor: Virginie Poulot, Laurence Baudrin, Maryvonne Pradere, Marie Wislez, Agnes Neuville, Jacques Cadranel, Sylvie Isaac-Sibille, Elisabeth Longchampt, Martine Antoine, Marie-Paule Lebitasy
Publikováno v: Lung cancer (Amsterdam, Netherlands). 68(2)
There is no optimal established therapy for treating advanced or recurrent adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC), and it remains unclear whether chemotherapy achieves therapeutic results comparable to those seen in the m
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7dc401b9390b5f4350db95dfab8ae12
https://pubmed.ncbi.nlm.nih.gov/19581016
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje